About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals (NASDAQ: AQXP) is a pharmaceutical company discovering and developing drug candidates to treat inflammation, inflammatory pain, and blood cancers. The company is dedicated to advancing therapeutics that it believes will make a clinically meaningful difference in patients' lives.
Missing: Aquinox Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aquinox Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aquinox Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aquinox Pharmaceuticals is included in 2 Expert Collections, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Aquinox Pharmaceuticals Patents
Aquinox Pharmaceuticals has filed 1 patent.
Analgesics, Clusters of differentiation, Inflammations, Amines, H1 receptor antagonists
Analgesics, Clusters of differentiation, Inflammations, Amines, H1 receptor antagonists
Latest Aquinox Pharmaceuticals News
Mar 23, 2022
March 23, 2022 08:00 AM Eastern Daylight Time BOSTON & DAEJEON, South Korea--( BUSINESS WIRE )-- Orum Therapeutics , a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to the Company’s Board of Directors. Mr. Main is a highly experienced biopharmaceutical executive who has more than 30 years of industry leadership experience with a strong track record of value creation and company growth. “David has extensive experience financing and leading biotech companies from early-stage research through commercial readiness,” said Sung Joo Lee, Ph.D., Founder and CEO of Orum Therapeutics. “I welcome David’s insight as Orum advances into clinical trials the Company’s first-in-class therapeutic candidates based on our Antibody neoDegrader Conjugate platform.” Orum’s Antibody neoDegrader Conjugate (AnDCTM) platform is built on novel targeted protein degrader (TPD) combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads (neoDegraders) to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death. “Orum’s AnDC platform combines the strengths of targeted protein degraders and antibody drug conjugates with a diversity of payloads needed to deliver precise tumor-killing action,” said Mr. Main. “I look forward to working with the Orum team and Board as the Company advances these innovative first-in-class tumor-directed targeted protein degraders into the clinic to improve the treatment of cancer.” The lead therapeutic programs from Orum’s AnDC platform are ORM-5029 and ORM-6151, potential first-in-class targeted protein degrader therapies for HER2-expressing breast cancer and CD33-positive acute myeloid leukemia (AML), respectively. Each program employs a different antibody drug to specifically deliver Orum’s lead neoDegrader to tumor cells. The company plans to file Investigational New Drug (IND) applications with the U.S. Food and Drug Administration (FDA) for ORM-5029 in 2022 and ORM-6151 in 2023. Mr. Main is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he co-founded in 2006, Mr. Main oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a Nasdaq-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, Mr. Main served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He received a BSc in pharmacy and an MBA from the University of British Columbia. About Orum Therapeutics Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD2™ approach to provide dual precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Company’s proprietary platforms generated using the TPD2 approach includes the Antibody neoDegrader Conjugate (AnDC™) platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, and Daejeon, South Korea. For more information, visit www.orumrx.com . Contacts
Aquinox Pharmaceuticals Frequently Asked Questions (FAQ)
When was Aquinox Pharmaceuticals founded?
Aquinox Pharmaceuticals was founded in 2004.
Where is Aquinox Pharmaceuticals's headquarters?
Aquinox Pharmaceuticals's headquarters is located at Suite 450 – 887 Great Northern Way, Vancouver.
What is Aquinox Pharmaceuticals's latest funding round?
Aquinox Pharmaceuticals's latest funding round is Acq - P2P.
How much did Aquinox Pharmaceuticals raise?
Aquinox Pharmaceuticals raised a total of $65.84M.
Who are the investors of Aquinox Pharmaceuticals?
Investors of Aquinox Pharmaceuticals include Sun Pharma, Ventures West, Johnson & Johnson Innovation, Pfizer Venture Investments, Baker Brothers Investments and 4 more.
Who are Aquinox Pharmaceuticals's competitors?
Competitors of Aquinox Pharmaceuticals include Humanetics, Cornerstone Pharmaceuticals, Neos Therapeutics, Catabasis Pharmaceuticals, Kereos, CoImmune, Bexion Pharmaceuticals, PNP Therapeutics, Deciphera Pharmaceuticals, Akebia Therapeutics and 49 more.
Compare Aquinox Pharmaceuticals to Competitors
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
Oxford BioTherapeuticsis focused on the targeted treatment of cancer.
Cylene Pharmaceuticals is a clinical-stage, private company developing small molecule drugs against newly validated cancer targets. Cylene has taken a position in the discovery and development of first-in-class cancer drugs that activate the p53 tumor suppressor and drugs that target the CK2 protein kinase. The Company's p53 Activator/Pol I program delivered CX-5461, a Phase I stage small molecule that activates p53 to kill cancer cells but not normal ones. Targeting Pol I provides the first path to selectively activating p53 in malignant but not normal, healthy cells. Similarly, Cylene's leadership in exploiting CK2-dependent pathways enabled the creation of the first-in-class, Phase II ready CX-4945 agent and CX-8184, the 2nd generation agent, that can serve as the drugs of choice in rational drug combinations for improved treatment outcomes against many cancer indications. Cylene's approach delivers agents that enable pharmaceutical companies to expand portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics.
Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.
Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.